Skip to content

Change in AP at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$3.1M+88.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$7.17M-141%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$3.58M+332%
AbbVie logo
AbbVieABBV
-$1.59B-129%
Revvity logo
RevvityRVTY
-$13.74M-255%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Arrowhead Research’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's change in AP?
Arrowhead Research (ARWR) reported change in AP of $15.26M in Q4 2025.
How has Arrowhead Research's change in AP changed year-over-year?
Arrowhead Research's change in AP increased by 397.3% year-over-year, from $3.07M to $15.26M.
What does change in AP mean?
The net change in money owed to suppliers for unpaid bills.
How do you interpret change in AP?
An increase suggests the company is delaying payments to preserve cash, while a decrease indicates faster settlement of liabilities.
How does change in AP compare across companies?
Standard across all industries; biotech firms often manage this based on clinical trial vendor payment cycles.